The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
Nathan Fowler
Michael WangDuring the 61st American Society of Hematology (ASH) meeting, Orlando, US, the Lymphoma Hub were pleased to host a discussion between Nathan Fowler and Michael Wang, both from the MD Anderson Cancer Center, Houston, US, on what are the promising updates in lymphoma at ASH 2019?
Nathan Fowler and Michael Wang discuss the results from the pivotal, multicenter, ZUMA-2 trial that investigated the use of CD19 chimeric antigen receptor (CAR) T-cell therapy, in adult patients with relapsed or refractory mantle cell lymphoma. They also discuss updates from the tazemetostat trial and talked about data from a study that combined lenalidomide and obinutuzumab to treat patients with follicular lymphoma in both the frontline and relapsed setting.
What are the promising updates in lymphoma at ASH 2019?